SCHEMBL23958625

SCHEMBL23958625

CC(C)(O)c1cc(C(O)(CN)C(F)(F)F)nc(-c2ccc(F)cc2)c1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 3/20 0.39
CNR2 P34972 4/20 0.35
ALDH1A1 P00352 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP3A4 P08684 3/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
NR3C2 P08235 1/20 0.33
CNR1 P21554 1/20 0.32
KDM4E B2RXH2 2/20 0.32
GRM2 Q14416 1/20 0.32
PTGS2 P35354 1/20 0.32
NPC1 O15118 1/20 0.32
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25686591 1.00 CFTR (0.39) CFTRCNR2ALDH1A1L3MBTL1CYP3A4
SCHEMBL30692531 1.00 CFTR (0.39) CFTRCNR2ALDH1A1L3MBTL1CYP3A4
SCHEMBL30211264 1.00 CFTR (0.39) CFTRCNR2ALDH1A1L3MBTL1CYP3A4
SCHEMBL25686593 1.00 CFTR (0.39) CFTRCNR2ALDH1A1L3MBTL1CYP3A4
SCHEMBL25687148 0.93 CFTR (0.38) CFTRCNR2ALDH1A1L3MBTL1CYP3A4
SCHEMBL23930046 0.93 CFTR (0.38) CFTRCNR2ALDH1A1L3MBTL1CYP3A4
SCHEMBL30007072 0.93 CFTR (0.38) CFTRCNR2ALDH1A1L3MBTL1CYP3A4
SCHEMBL25687150 0.93 CFTR (0.38) CFTRCNR2ALDH1A1L3MBTL1CYP3A4
SCHEMBL25285421 0.93 CFTR (0.38) CFTRCNR2ALDH1A1L3MBTL1CYP3A4
SCHEMBL23930052 0.91 TRPV1 (0.35) CFTRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023237732-A1 RSV INHIBITING TRIAZOLO BEARING DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2023-12-14 WO disclosed
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
WO-2021214136-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE CFTR 508/4885CNR2 646/4885ALDH1A1 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.